Literature DB >> 18136192

Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions.

J B GRAHAM, J A BUCKWALTER.   

Abstract

A study was made of the clotting defect and the course of the malady in a group of male dogs with an inherited, sex-linked bleeding disease. The clotting defect is characterized by a prolonged clotting time and a delayed prothrombin utilization, and is corrected by the addition either of thromboplastin or of normal plasma. A plasma protein fraction, fraction I, also corrects the defect. The defect appears to be due to a deficiency of a plasma factor, which normally, in the presence of platelets, makes thromboplastin available in shed blood. The clotting anomaly appears to be identical with that found in human hemophilia. The hemostatic defect is characterized by repeated hemorrhages, usually without obvious relationship to trauma. Hemarthroses occur frequently and may result in permanent joint deformity. The animals usually die early in life from massive hemorrhage. Transfusions with normal blood or plasma correct the clotting defect and readily control the hemorrhagic phenomena. By the use of transfusions, these dogs have been reared to maturity.

Entities:  

Keywords:  HEMOPHILIA

Mesh:

Substances:

Year:  1949        PMID: 18136192      PMCID: PMC2135899          DOI: 10.1084/jem.90.2.97

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  Normal and Abnormal Blood Coagulation: A Review.

Authors:  R G Macfarlane
Journal:  J Clin Pathol       Date:  1948-05       Impact factor: 3.411

2.  Recent advances in our knowledge of prothrombin; a brief review.

Authors:  W H SEEGERS; A G WARE
Journal:  Am J Clin Pathol       Date:  1949-01       Impact factor: 2.493

3.  PROTHROMBIN DEFICIENCY AND THE BLEEDING TENDENCY IN LIVER INJURY (CHLOROFORM INTOXICATION).

Authors:  H P Smith; E D Warner; K M Brinkhous
Journal:  J Exp Med       Date:  1937-11-30       Impact factor: 14.307

  3 in total
  20 in total

1.  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

Authors:  Jennifer A Dumont; Tongyao Liu; Susan C Low; Xin Zhang; George Kamphaus; Paul Sakorafas; Cara Fraley; Douglas Drager; Thomas Reidy; Justin McCue; Helen W G Franck; Elizabeth P Merricks; Timothy C Nichols; Alan J Bitonti; Glenn F Pierce; Haiyan Jiang
Journal:  Blood       Date:  2012-01-13       Impact factor: 22.113

2.  Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.

Authors:  T Knudsen; A T Kristensen; T C Nichols; H Agersø; A L Jensen; M Kjalke; M Ezban; M Tranholm
Journal:  Haemophilia       Date:  2011-06-06       Impact factor: 4.287

3.  Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.

Authors:  Randolph B Lyde; Hyun Sook Ahn; Karen K Vo; Danuta J Jarocha; John Tkaczynski; Elsa Treffeisen; Spencer K Sullivan; Rodney M Camire; Denise E Sabatino; Deborah L French; Mortimer Poncz
Journal:  Blood Adv       Date:  2019-05-14

Review 4.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 5.  Animal models of hemophilia and related bleeding disorders.

Authors:  Jay N Lozier; Timothy C Nichols
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

6.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

7.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Authors:  Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

10.  Lessons Learned from Animal Models of Inherited Bleeding Disorders.

Authors:  Timothy C Nichols
Journal:  Hematol Educ       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.